Featuring: STPs and Pharma; AI in R&D; Secondary patent battles
Sustainability and Transformation Plans (STPs) are set to create upheaval in the NHS – and in the pharma industry too
PharmaTimes speaks to AI expert Jackie Hunter about the future of these technologies in R&D
UK groups Glythera and IONTAS are working together on the development of antibody drug conjugates for difficult-to-treat cancers.
20th September 2017
Data from a Phase III study evaluating Shire’s Intuniv in Japan in adults with attention deficit hyperactivity disorder indicate that the drug could improve symptoms of the condition in this patient group.
20th September 2017
The European Commission has approved Novartis’ Rydapt to treat a certain form of acute myeloid leukaemia (AML) as well as three other rare diseases.
20th September 2017
Bristol-Myers Squibb’s Opdivo is being recommended by the National Institute for Health and Care Excellence to treat a certain form of lung cancer on the NHS in England, via the Cancer Drugs Fund.
20th September 2017
Janssen has unveiled new data showing consistent rates of skin clearance with guselkumab treatment among patients with moderate to severe plaque psoriasis.
19th September 2017
Why life sciences shouldn't overlook UX
Joseph B. Laudano, vice president, medical affairs strategy for Medmeme, takes a look at advances in data mining and metrics analysis
In a world of increasingly complex pharma supply chains, technology is playing a growing role in helping smooth the relationship between businesses and their suppliers
A detailed look at the ongoing patent case for Pfizer’s pain drug and what the potentially-landmark ruling could mean for the industry
How to become investigator sites’ payments sponsor of choice
How targeted digital advertising could help pharma marketers avoid some of the industry’s most common pitfalls
Paul Midgley, director of NHS Insight at Wilmington Healthcare, explains how Capped Expenditure Processes (CEP) will impact both NHS services and pharma sales
Inside the technological, legislative and financial checks on the rise of genome-based medicine
Jaak Peeters, head of Johnson & Johnson Global Public Health, on pharma’s role in supporting global health, fighting epidemics and making medicines accessible
The unusual circumstances of Fujifilm and AbbVie’s Humira patent case and its potential impacts on the market
The NHS scores better than many other countries in terms of access to health – until you take outcomes into account
PharmaTimes speaks to AI expert Jackie Hunter about the future of these technologies in R&D
Biologic drugs are big. A heterogeneous mixture of more than 1,300 weighty amino acids, they are hundreds of times the 1- to 2 ml size of conventional small molecule injectables. That renders them hard to make - and even harder for patients to take.
Jeff Zucker of Worldwide Clinical Trials explains the key to improving study site performance
When we ignore carers, we miss out on one of our best shots at driving treatment success, says David Hunt, CEO of Havas Lynx
Across all industries, people are changing the ways they engage with products, services, and brands. View more...
Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW
